A Critical Eye on Progress: FDA Official Questions uniQure's Huntington's Trial Comparisons

The Shifting Sands of Pharma: FDA's Grip, Global Ambitions, and the Future of Medicine

A Major Setback: FDA Halts uniQure's Huntington's Gene Therapy Trial

The Quiet Hum of Hope and High Stakes: Unpacking the Future of Huntington's Treatment

The Gene Therapy Dream Interrupted: UniQure Investors Face an Unsettling Inquiry

The Whisper of an Exit: What Jack Kaye's uniQure Stock Sale Could Tell Us

The FDA's Tightening Grip: A Crucible for Biotech's Biggest Bets

uniQure's Explosive 248% Rally: Why Wall Street Believes the Best is Yet to Come

Biotech Sensation: uniQure's Huntington's Breakthrough Fuels Historic Stock Surge

A New Horizon of Hope: uniQure's AMT-130 Shines with Positive 3-Year Data in Huntington's Disease

A Beacon of Hope: uniQure's AMT-130 Gene Therapy Shines in Huntington's Disease Trial